Here are the strategies of Novo’s rivals
Two of Novo Nordisk’s fiercest rivals have very distinct strategies in the battle for control of the global diabetes market. Medwatch has spoken to key people from Sanofi and Eli Lilly.
by Stefan Singh Kailay
Sanofi and Eli Lilly are at two different stages at the moment. In the drug Lantus, Sanofi has the world’s by far bestselling diabetes drug – in fact, with a sales increase of 1.4 billion dollars it was the global pharmaceutical industry’s fastest growing drug in 2012. Eli Lilly, on the other hand, is in the process of returning to the lead group after having fallen behind within diabetes in recent years.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
.jpg&w=384&q=75){kind=logo}
